Sarcoidosis Market is segmented by Type (Pulmonary, Ocular, Neurosarcoidosis, Cardiac, Musculoskeletal, Cutaneous, Renal, Hepatic Sarcoidosis, Sarcoidosis of the Spleen and Bone Marrow); by Mechanism of Action (Corticosteroid, Immunosuppressant, Antimalarial, Tumor Necrosis Factor-Alpha Inhibitors); by Drug Type (Corticotropin, Chloroquine, Dexamethasone, Colchicine, Prednisone, Methotrexate, Hydroxychloroquine, Azathioprine, Deltasone); by End User (Hospital Clinics, Surgical Centers, Diagnostic Centers, Others); by Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) - Global Market Analysis, Trends, Opportunity and Forecast, 2023-2032

Sarcoidosis Market Overview

The global sarcoidosis market was valued at USD 23.1 billion in 2023. The market is expected to expand at a CAGR of 14.2% from 2023-2032, and is expected to cross value of USD 61.2 billion by the end of 2032.

Sarcoidosis is a condition which is characterized by the growth of granulomas or the tiny collection of inflammatory cells in the lungs, skin, lymph nodes, or any other body part. The disease can be asymptomatic and is usually discovered in about 5% of the cases, that too by accident. One of the major factors predicted to contribute to the growth of the sarcoidosis market is the rise in public awareness for the disease, majorly promoted by government and non-government organizations. For instance, in the United States, the Foundation for FSR and the National Heart, followed by the NIH’s Lung and Blood Institute (NHLBI) are raising awareness for the disease in the nation, whereas, in the United Kingdom, the British Lung Foundation (BLF) is focusing upon sharing information as how to diagnose and treat the disease. Advenchen Laboratories, LLC, Merck & Co., Inc., and Bellus Health Inc. are some of the significant parties in the market for sarcoidosis.

                                    Get More Insights on This Report - Request Free Sample PDF

Sarcoidosis Market Drivers

Some key drivers for the sarcoidosis market are:

• Growing Focus on Raising Public Awareness for the Disease: One of the major factors expected to boost the growth of the sarcoidosis market is the increase in focus of both governmental and non-governmental organizations in generating public awareness for the disease and how to treat it.
• Surge in Funding for Research: Despite of multiple research been done on sarcoidosis, the etiology of the disease is not yet known, and a promising treatment for the disease is not yet available. As a result, both the government and private organizations are releasing funds to promote the research on the disease for the innovation of promising therapeutics. For instance, the FSR has awarded about USD 4.1 million in grants just a few years back, and has also provided research support, along with annual research awards and abstract awards to selected programs to encourage the pharmaceutical companies and universities to develop promising therapeutics.
• Increasing Development of Biosimilar for Immunosuppressant: Owing to the numerous benefits associated with the development of biosimilars than the original drug, the pharmaceutical manufacturers are increasingly focusing upon developing biologics or biosimilars. These biological agents have a resemblance to reference products that are licensed and authorized currently by the U.S. Food and Drug Administration.
• Rise in Prevalence of Sarcoidosis: Globally, more than 25 million people were known to have sarcoidosis in the year 2022 and the rate of mortality from the disease is also increasing year on year. Owing to this rising prevalence for the disease, the need for treating the disease would also increase, which is expected to contribute to the market growth.

Sarcoidosis Market Challenges

Some challenges facing the sarcoidosis market are:

• Stringent Drug Approval Process: The regulatory bodies have set stringent procedures for the approval of drugs for the treatment of sarcoidosis. Such a factor delays the overall drug development process and also increases the cost of developing a new drug, thereby impacting negatively towards the market growth.
• Several Complications Associated with the Treatment of the Disease: Till date, a proper easy treatment for the disease is not yet available, and whatever choices are currently available, those possesses numerous complications. Due to this complicated treatment procedures, the market growth is expected to be significantly hampered.
• Less Awareness for the Disease in Under-Developed Regions: Several under-developed or partially developing regions around the globe, yet, do not have any awareness programs being set by the government or private organizations to raise awareness about the disease. As a result, the disease is not being identified in most of the patients, creating an opportunity loss for the expansion of the market.

Sarcoidosis Market Segmentation

Segmentation of sarcoidosis market are:

• By Type
  • Pulmonary
  • Ocular
  • Neurosarcoidosis
  • Cardiac
  • Musculoskeletal
  • Cutaneous
  • Renal
  • Hepatic Sarcoidosis
  • Sarcoidosis of the Spleen
  • Bone Marrow
• By Mechanism of Action
  • Corticosteroid
  • Immunosuppressant
  • Antimalarial
  • Tumor Necrosis Factor-Alpha Inhibitors
• By Drug Type
  • Corticotropin
  • Chloroquine
  • Dexamethasone
  • Colchicine
  • Prednisone
  • Methotrexate
  • Hydroxychloroquine
  • Azathioprine
  • Deltasone
• By End User:
  • Hospital Clinics
  • Surgical Centers
  • Diagnostic Centers
  • Others
• By Region
  • North America (U.S., and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa

Timeline considered for all these studies will be:

2023 – Base Year

2023 – Estimated Year

2023-2032 – Forecast Period

Sarcoidosis Market Regional Synopsis

The Europe sarcoidosis market is projected to hold the largest market share by the end of 2032. Increasing focus of the pharmaceutical organizations in the region for developing orphan drugs for treating the disease, along with the rise in prevalence of the disease, particularly in Switzerland, is expected to boost the market growth. Recently, the European Commission has granted the lead therapeutic candidate by Tyr Pharma, known as efzofitimod, the orphan drug designation for treating the disease.

Further, the North America sarcoidosis market is projected to grow with the highest CAGR during the forecast period, supported by the rise in investment for research and development by major pharmaceutical players of the region for the development of drugs for treating the disease. Besides this, the growing health expenditure in the region is also poised to boost the market growth in the coming years. Recently, the United States recorded near to USD 132 billion in health expenditure, also being one of the largest health expenditure nations worldwide.

Sarcoidosis Market Key Players

Some key players in the sarcoidosis market are:

• Advenchen Laboratories, LLC
• Merck & Co., Inc.
• Bellus Health Inc.
• Novartis AG
• Adaptimmune Therapeutics Plc
• Pharmain Corp
• Firststring Research
• Epizyme, Inc
• Relief Therapeutics Holding SA
• Araim Pharmaceuticals Inc.
• Auven Therapeutics
• Fresenius Umwelttechnik GmbH
• Horizon Therapeutics plc
• Johnson & Johnson Services, Inc.
• Pfizer Inc.